{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:22:28Z","timestamp":1792686148779,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e37040","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:47:13Z","timestamp":1724878033000},"page":"e37040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Libo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.heliyon.2024.e37040_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e37040_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14740338.2018.1549222","article-title":"Safety of osimertinib in EGFR-mutated non-small cell lung cancer","volume":"17","author":"Mezquita","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37040_bib3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/10428191003763468","article-title":"Treatment of therapy-related myeloid neoplasms with high-dose cytarabine\/mitoxantrone followed by hematopoietic stem cell transplant","volume":"51","author":"Godley","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37040_bib4","first-page":"315","article-title":"Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report","volume":"38","author":"Tang","year":"2016","journal-title":"Malays. J. Pathol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e37040_bib5","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/sj.leu.2404851","article-title":"Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia","volume":"21","author":"Ravindranathan","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37040_bib6","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.005","article-title":"Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: monocentric observational study and review of the literature","volume":"10","author":"Metafuni","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e37040_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood.2021010764","article-title":"What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms","volume":"138","author":"Voso","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37040_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18154","article-title":"Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype","volume":"197","author":"Tariq","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e37040_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/0970-258X.321138","article-title":"Chronic myeloid leukaemia after chemoradiotherapy for solid malignancies","volume":"33","author":"Baysal","year":"2020","journal-title":"Natl. Med. J. India"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37040_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.anndiagpath.2006.12.002","article-title":"New insights into the pathobiology and treatment of chronic myelogenous leukemia","volume":"11","author":"Cotta","year":"2007","journal-title":"Ann. Diagn. Pathol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37040_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002770050527","article-title":"Treatment-related chronic myelogenous leukemia","volume":"78","author":"Waller","year":"1999","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37040_bib12","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system","volume":"10","author":"Huang","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e37040_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJM200502243520825","article-title":"APL during gefitinib treatment for non-small-cell lung cancer","volume":"352","author":"Uchida","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37040_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1532\/IJH97.06149","article-title":"A case of acute promyelocytic leukemia during gefitinib treatment","volume":"84","author":"Ennishi","year":"2006","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e37040_bib15","first-page":"973","article-title":"Serious hematologic complications following erlotinib treatment","volume":"30","author":"Stathopoulos","year":"2010","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37040_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3343\/alm.2014.34.2.155","article-title":"Therapy-related acute megakaryoblastic leukemia in a lung cancer patient","volume":"34","author":"Moon","year":"2014","journal-title":"Ann Lab Med"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e37040_bib17","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.12998\/wjcc.v9.i24.7205","article-title":"Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: a case report","volume":"9","author":"Koo","year":"2021","journal-title":"World J Clin Cases"},{"issue":"35","key":"10.1016\/j.heliyon.2024.e37040_bib18","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1200\/JCO.2008.19.5685","article-title":"Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia","volume":"26","author":"Hotta","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e37040_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2015.258","article-title":"Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation","volume":"30","author":"Radivoyevitch","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e37040_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41379-021-00958-9","article-title":"Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis","volume":"35","author":"Liu","year":"2022","journal-title":"Mod. Pathol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e37040_bib21","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e37040_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/JBM.S29132","article-title":"Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia","volume":"3","author":"Baran","year":"2012","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37040_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e37040_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e37040_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13256-016-1180-4","article-title":"Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report","volume":"11","author":"Elm'hadi","year":"2017","journal-title":"J. Med. Case Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402413071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402413071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:38:59Z","timestamp":1790545139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402413071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S240584402413071X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37040","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e37040"}}